OBJECTIVE： To investigate clinical efficacy and safety of breviscapine combined with vinpocetine in the treatment of acute cerebral infraction. METHODS： A total of 80 patients with acute cerebral infraction were selected from our hospital during Jan. 2014-Dec. 2015， and then divided into observation group and control group according to random number table， with 40 cases in each group. Control group was given Vinpocetine injection 20 mL+0.9％ Sodium chloride injection 250 mL， ivgtt， qd. Observation group was additionally given Breviscapine injection 20 mL+5％ Glucose injection 250 mL， ivgtt， qd， at intervals of 2-3 h on the basis of control group. Both groups were treated for 2 weeks. Clinical efficacies as well as serum copeptin， NT-proBNP， albumin cobalt binding （ACB） value， European stroke scale （ESS） and functional independence measurement （FIM） score before and after treatment were observed in 2 groups， and the occurrence of ADR was recorded. RESULTS： Total response rate of observation group （90.0％） was significantly higher than that of control group （67.5％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in serum peptide， NT-proBNP， ACB value， ESS or FIM score between 2 groups （P＞0.05）. After treatment， serum copeptin and NT-proBNP levels of 2 groups were decreased significantly， while ACB value， ESS and FIM score were increased significantly； the improvement of observation group was significantly better than that of control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Breviscapine combined with vinpocetine can improve neurological function of acute cerebral infraction patients and show good therapeutic efficacy with good safety.